China At Forefront Of Next Generation Sequencing: BGI CEO
This article was originally published in PharmAsia News
Executive Summary
From screening for cancer to providing individualized treatment, from rare diseases to the first in vitro fertilized (IVF) baby with modified genes, China has much to offer in the heating global race for next generation gene sequencing. Big data and the internet of genomics are just some examples, says Wang Jun, CEO of BGI, the world’s largest genomics organization.
You may also be interested in...
China Drug Price Negotiations: Another Race To The Bottom？
With the fourth quarter just around the corner, China's closely-watched annual drug reimbursement and prices negotiations are entering a key final stage. But will applicants need to be more strategic than expedient?
Chinese-Language Podcast: ESMO上的中国数据
Special guest, Citeline's Annie Siu, discusses the recent ESMO meeting and Jiangsu Hengrui and BeiGene's PD-1 data for hepatocellular carcinoma in this latest episode of the Chinese-language China Biotech podcast.
Cell, Gene Therapy A No Entry Zone? EU Group Seeks Clarification Over China Regs
China’s Negative List for Foreign Investment explicitly bars “investment and application in human stem cells, genetic diagnosis, and treatment technologies.” But whether that applies to foreign pharma firms developing such modalities in the country remains unclear.